J Biol Chem, Vol. 274, Issue 17, 11473-11478, April 23, 1999

Full Peptide Synthesis, Purification, and Characterization of Six Tat Variants
DIFFERENCES OBSERVED BETWEEN HIV-1 ISOLATES FROM AFRICA AND OTHER CONTINENTS^*

Jean-Marie Péloponèse Jr.^§, Yves Collette^¶, Catherine Grégoire, Christian Bailly^**, Daniel Campèse, Eliane F. Meurs, Daniel Olive^¶, and Erwann P. Loret^§§

From the  Laboratoire d'Ingénierie des Systèmes Macromoléculaires, Institut de Biologie Structurale et Microbiologie, CNRS UPR 9027, 31 Chemin Joseph Aiguier, 13402 Marseille, France, the ^¶ Unité de Cancerologie Expérimentale, INSERM U 119, 27 Boulevard Leî Roure, 13009 Marseille, France, the ^** Institut de Recherche sur le Cancer, INSERM U 124, Place de Verdun, 59045 Lille, France, and the  Unité de Virologie et Immunologie Cellulaire, Institut Pasteur, 28 rue du Dr. Roux, 75015 Paris, France

	ABSTRACT

TOP ABSTRACT INTRODUCTION MATERIALS AND METHODS RESULTS AND DISCUSSION REFERENCES

AIDS in Africa is characterized by the equal distribution of mortality between the two genders because of highly virulent human immunodeficiency virus type 1 (HIV-1) strains. The viral protein Tat trans-activates viral gene expression and is essential for HIV-1 replication. We chemically synthesized six different Tat proteins, with sizes ranging from 86 to 101 residues, from HIV-1 isolates located in different parts of the world including highly virulent African strains. Protein purification, mass spectroscopy, and amino acid analysis showed that the synthesis was successful in each case but with different yields. We show that all have the ability to bind the HIV long terminal repeat (LTR) RNA trans-activation response element (TAR) region, involved in Tat-mediated trans-activation, but structural heterogeneities are revealed by circular dichroism. These Tat synthetic proteins cross membranes but differ in their ability to trans-activate an HIV LTR-reporter gene in stably transfected HeLa cells. Two Tat proteins from virulent African HIV-1 strains were much more active than those from Europe and the United States. The interferon-induced kinase (PKR), involved in cell antiviral defense, phosphorylates only Tat variants corresponding to less or nonvirulent HIV-1 isolates. Our results indicate that the high virulence of some African HIV-1 strains could be related to Tat activity.

	INTRODUCTION

TOP ABSTRACT INTRODUCTION MATERIALS AND METHODS RESULTS AND DISCUSSION REFERENCES

The HIV¹ encodes regulatory proteins such as Tat, which profoundly affect the course of viral gene expression in infected cells. Tat stimulates the production of full-length viral transcripts by RNA polymerase II (1, 2). This function is generally associated with the ability of Tat to bind the nascent leader RNA hairpin TAR located at the 5'-end of all HIV-1 mRNAs (3). Tat presents a highly conserved basic region that can adopt an extended structure to fit into the TAR major groove (4). Furthermore, this basic region provides for Tat the capacity to cross membranes (5, 6).

However, the role of Tat in the HIV cycle is more than to facilitate the elongation of HIV mRNA. Tat is required for efficient HIV-1 reverse transcription (7). Activities of different cellular kinase is modulated by Tat, which results in the activation of viral transcription in infected cells (8, 9). Tat protein is released from HIV-1-infected cells and can be detected in sera from HIV-1-infected patients (10). Extracellular Tat may account for the decrease of the host immune response and cellular disorders connected to AIDS pathology. Tat in synergy with a basic fibroblast growth factor (bFGF) is involved in the induction of Kaposi's sarcoma lesions (11). Tat is able to repress the major histocompatibility complex (MHC) class I genes and provides the virus with a mechanism to evade the host immune response (12). Finally, Tat participates in the induction of apoptosis in lymphocytes and contributes to the depletion of the CD4+ T cells in AIDS (10, 13).

One of the primary cellular responses to viral infection is the production of interferon. The double-stranded RNA-dependent protein kinase (PKR) is induced by interferon and can be activated by double-stranded RNA such as the HIV RNA (14). Following its activation, PKR in turn inactivates the initiation factor eIF2, leading to the inhibition of protein synthesis, which can be detrimental for the viral life cycle. Overexpression of PKR in HIV-1-infected cells was recently shown to inhibit the replication of the virus (15). However, interferon does not have a strong antiviral action during the course of natural infection. Tat was shown to inhibit the PKR activity in vitro and therefore Tat may contribute to the HIV resistance to interferon (16). Interestingly, once activated, PKR is able to phosphorylate Tat but the physiological significance of this phosphorylation is not known (17).

Tat is encoded by two exons and its second exon can be variable in size depending on the nature of the HIV-1 isolates (18). Most structural studies on Tat are made with a Tat protein 86 residues long, corresponding to the Bru HIV-1 isolate (19) or a closely related sequence from the HXB2 HIV-1 isolate (20). However, the analysis of Tat protein sequences allowed us to identify six structural groups (21).

In this study, we have chemically synthesized six Tat proteins representative of each structural group. We show that all have the ability to bind the HIV LTR TAR region but structural heterogeneities appeared when analyzed by circular dichroism. Interestingly, these synthetic proteins cross membranes but differ in their ability to trans-activate an HIV LTR-reporter gene in stable transfected HeLa cells. We show a correlation between the rate of trans-activation, the Tat-PKR interaction, and HIV-1 virulence.

	MATERIALS AND METHODS

TOP ABSTRACT INTRODUCTION MATERIALS AND METHODS RESULTS AND DISCUSSION REFERENCES

Protein Synthesis, Purification, and Characterization-- Peptides were assembled according to the method of Barany and Merrifield (22) on HMP preloaded resin (0.5-0.65 mmol) (Perkin Elmer, Applied Biosystem Inc., Forster City, CA) on an automated synthesizer (ABI 433A, Perkin Elmer, Applied Biosystem Inc.). To avoid derivatives with deletion, the N-terminal extremities without Fmoc were capped with a 4.75% acetic anhydre (Merck), 6.25% DIEA 2.0 M, 1.5% 1-hydroxybenzotriazol 1 M (HOBt) (Perkin Elmer, Applied Biosystem Inc., Warrington, UK), and 87.5% N-methylpirrolidone (Perkin Elmer). Each deprotection step was monitored with a conductivity device. The peptides were deprotected and removed from the resin with trifluoroacetic acid (TFA) complemented with 10% methylphenyl sulfide (Merck) and 5% ethanedithiol (Merck) as scavenger. Purification was done with Beckman high pressure liquid chromatography (HPLC) apparatus and a Merck C8 reverse-phase column (10 × 250 mm). Buffer A was water with 0.1% TFA and buffer B was acetonitrile with 0.1% TFA. Gradient was buffer B from 20 to 40% in 40 min with a 2 ml/min flow rate. HPLC analysis was done with a Merck C8 reverse phase column (4 × 125 mm) with similar buffers but a gradient from 10 to 50% B in 40 min and a 0.8 ml/min flow rate. Electrospray mass spectrometry was carried out with a Perkin Elmer single quad PE-SCIEX API 150ex. Amino acid analyses were performed on a model 6300 Beckman analyzer.

Electrophoretic Mobility Shift Assays-- The 59-nucleotides TAR RNA containing the essential UUU pyrimidine bulge was prepared by in vitro T3 RNA polymerase transcription. Binding reaction mixtures (20 µl) contained 0.2 nmol of radiolabeled TAR RNA, 0-100 ng of Tat in TK buffer (50 mM Tris, pH 7.4, 20 mM KCl, 0.1% Triton X-100). Complexes were separated from unbound RNA by electrophoresis in nondenaturing 8% polyacrylamide gels containing 0.1% Triton X-100. The gel was pre-run for 30 min before loading the sample (25 µl). The electrophoresis was continued for 90 min at about 200 V. The relative amounts of free and/or bound RNA were determined by phosphoimaging.

Circular Dichroism-- CD spectra were measured with a 50-µm path length cell from 260 to 178 nm on a Jobin-Yvon (Long-Jumeau, France) UV CD spectrophotometer (Mark VI). The instrument was calibrated with (+)-10-camphorsulfonic acid. A ratio of 2.1 was found between the positive CD band at 290.5 nm and the negative band at 192.5 nm. Data were collected at 0.5 nm intervals with a scan rate of 1 nm per min. CD spectra are reported as per amide. The samples were prepared in 20 mM phosphate buffer, pH 4.5, or in 50% trifluoroethanol (TFE). Protein concentrations were in a range from 0.5 to 1 mg/ml.

Trans-activation with HIV LTR Transfected Cells-- Functional trans-activation by synthetic Tat was assessed using P4 cells. These HeLa-CD4 cells carry the bacterial lacZ gene under the control of the HIV LTR, and cytoplasmic accumulation of -galactosidase is strictly dependent on the presence of Tat. 80% confluent cells plated in a 12-well plate were incubated for 24 h at 37 °C, 5% CO₂, with Tat protein contained in DMEM medium supplemented with 0.1% BSA. Following this incubation period, cells were washed with phosphate-buffered saline, proteins were extracted and analyzed for -galactosidase using the commercial antigen capture enzyme-linked immunosorbent assay (-galactosidase ELISA, Boehringer Mannheim, France), according to the manufacturer instructions. Values were normalized using the concentration of total proteins of the various cell lysates as determined by the Bradford method.

In Vitro Phosphorylation-- Monoclonal antibodies directed against PKR were first bound to protein A-agarose for 60 min at room temperature (1 µl Mab/100 µl agarose) in buffer I (20 mM Tris-HCl, pH 7.6, 40 mM NaCl, 50 mM KCl, 1% Triton X-100, 1 mM EDTA, 0.05% aprotinin, 0.2 mM phenylmethylsulfonyl fluoride, 5 mM 2-mercaptoethanol, 25% glycerol). The beads were washed three times in buffer I and incubated with cytoplasmic extracts from interferon-treated Daudi cells at 4 °C for 20 h (extracts equivalent to 10⁶ cells/100 µl of beads). They were then washed three times in buffer I, further washed three times with buffer II (20 mM Tris-HCl, pH 7.6, 100 mM KCl, 0.1 mM EDTA, 0.05% aprotinin, 20% glycerol), and resuspended in buffer III (buffer II supplemented with 2 mM MgCl₂). For the phosphorylation reaction, each sample (30 µl of beads) was incubated with 40 µl of buffer III supplemented with 2 mM MnCl₂ and 10 µl of [³²P-]ATP solution (1.25 mCi/ml [³²P-]ATP (3000 Ci/mmol; ICN), 10 µM ATP, 1 mM MgCl₂ in buffer II). The reaction was performed in the absence or in the presence of 1 µg/ml of poly(I)·poly(C) (Amersham Pharmacia Biotech). After incubation for 15 min at 30 °C, eIF2 (2 µl of a purified preparation; gift of Christopher Proud) or the different Tat proteins (0.2 to 0.4 µg) were added, and the reaction was continued for another 15 min. All Tat proteins come from 100 µg of lyophilized proteins resuspended in 100 mM phosphate buffer, pH 4.5, containing 5% bovine serum albumin. For PKR phosphorylation assay, they were diluted 10 times in buffer II supplemented with 2 mM MgCl₂ and 2 mM MnCl₂ and added immediately to the incubation mix. At the end of the incubation, an equal volume of 2× protein electrophoresis buffer was added, and the products were analyzed by SDS-polyacrylamide gel electrophoresis on 17.5% polyacrylamide gels.

	RESULTS AND DISCUSSION

TOP ABSTRACT INTRODUCTION MATERIALS AND METHODS RESULTS AND DISCUSSION REFERENCES

The six Tat proteins representative of each structural group were synthesized with a Fast Fmoc chemistry in solid phase synthesis (22). Tat Bru (86 residues) and Tat Jr (101 residues) have similar sequences and are representative of HIV-1 isolates found in Europe and North-America (20, 23). Tat Oyi (101 residues) also has similarities with European and North American Tat sequences but was identified from a healthy Gabones man bearing a defective HIV-1 strain (24). Tat Z2 (86 residues) came from a Zairian HIV-1 isolate and is closely related to an ancestral HIV-1 isolate (ZR59) identified recently (25). Tat Z2 is the closest of the ancient forms of Tat proteins. In contrast, Tat Mal (87 residues) and Tat Eli (99 residues) appeared more recently and came from highly virulent HIV-1 isolates recovered, respectively, from a 24-year old woman and a 7-year old boy in Zaire (now Democratic Republic of Congo) following a dramatic increase of AIDS in central Africa during the 1980s (26).

Each chemical synthesis was done in a single run using a fast Fmoc chemistry. We use an HBTU activator in each case, and deprotection was monitored by the measurement of the conductivity. The first sequence to be synthesized was Tat Bru (Fig. 1) with carboxymethylated cysteines (Cm-Cys Tat Bru). Previous peptide syntheses were carried out with Tat HXB2 (86 residues), which has a sequence very close to Tat Bru (27, 28). After purification of Cm-Cys Tat Bru (data not shown), our synthetic protein showed that it could bind TAR RNA (Fig. 3) but could not trans-activate in our HeLa cell assay. The position of the seven cysteine residues is strictly conserved among Tat variants and the importance of cysteine residues for trans-activation is well described in the literature (18). This explains why Cm-Cys Tat Bru does not trans-activate in our HeLa cells assay. Another synthesis of Tat Bru was done with free cysteines this time. This synthetic protein turned out to be able to bind TAR (Fig. 3) and trans-activates in our HeLa cell assay (Fig. 5). To avoid precipitation that occurred at neutral pH, the Tat proteins were dissolved in phosphate buffer at pH 4.5 and then directly mixed to the cell medium that has a neutral pH. Probably the different ions present in cell medium neutralized the cysteines. In these conditions, which were rather close to those encountered by Tat in the blood of HIV infected patients, we observed a much higher trans-activation activity (Fig. 5) compared with what was previously reported with synthetic Tat proteins. Therefore, all the other synthetic Tat variants were done with free cysteines.

View larger version (9K): [in this window] [in a new window]   Fig. 1.   Amino acid sequences of the six Tat variants synthesized. The sequences are compared with Tat Bru which represents the sequence most used in laboratories and comes from an HIV-1 isolated in France (19), whereas Tat Jr come from an American HIV-1 isolate (23). Tat Oyi is closely related to Tat Jr and Tat Bru but comes from an HIV-1 identified in a healthy patient in Gabon (24). Tat Z2 comes from an HIV-1 isolate close to ancestral strains of the virus (25). Tat Mal and Tat Eli comes from HIV-1 strains isolated during the 1980s in central Africa following a burst of HIV heterosexual infection (26).

Peptide synthesis starts from the C-terminal extremity and the yield of synthesis for the first 50 residues was from 90 to 98% as a function of the Tat sequence. This yield decreased significantly beyond this level for Tat Bru, Tat Jr, and Tat Oyi and are revealed by the HPLC analysis of the synthesis before purification (Fig. 2). The conductimetry analysis of the deprotection steps revealed that the sequence just after the basic region was critical (data not shown). Tat Eli is the sequence that gave the best synthesis yield and a significant decrease in conductimetry was observed only from step 88. For Tat Mal, the final deprotection was not carried out, and half of the crude peptide was cleaved from the resin with an Fmoc on at the N terminus. This gave a 10-min shift for the major fraction in the analytical HPLC and could have been helpful for the purification (Fig. 2E). Unfortunately it was not possible to have soluble Tat after the removal of the Fmoc even in the presence of a solution containing 6 M guanidine and dithiothreitol (data not shown). The Fmoc was removed before cleavage for the other Tat and in the crude peptide remaining from Tat Mal (data not shown). The final yield after synthesis and purification varied from 5% for Tat Jr to 16% for Tat Eli. The purity and characterization of the Tat proteins were determined by analytical HPLC (Fig. 2), mass spectroscopy, and amino acid analysis (data not shown). In each case, the results indicated that we obtained a pure protein with the correct molecular weight and the expected amino acid composition.

View larger version (20K): [in this window] [in a new window]   Fig. 2.   HPLC analyses. HPLC was carried out with a C8 reverse phase column at 280 nm (see "Materials and Methods" for the experimental procedure). For each panel, the lower run shows the result of the peptide synthesis before purification, whereas the upper run shows the result after the last purification step. Tat Bru (A), Tat Jr (B), Tat Z2 (C), Tat Oyi (D), Tat Mal (E), and Tat Eli (F) were cleaved from the resin with TFA. After precipitation with butylmethyl ether, the proteins were dissolved in 0.1% TFA buffer (lower runs in each panel). For each protein, purification was done with two successive semipreparative HPLC runs, and then the pure fractions were analyzed (upper runs in each panel) and identified by mass spectroscopy and amino acid analysis (data not shown). In each case, the major HPLC peak turned out to be the full sequence. Peaks between 10 and 15 min are derivatives of 50 residues, whereas peaks close to the major fraction are derivatives with one to fifteen deletions from the N terminus. Highly hydrophobic fractions were derivatives with a high molecular weight probably because of side chain incomplete deprotections.

The six synthetic Tat proteins can bind to TAR RNA (Fig. 3) and can inhibit PKR (data not shown). Nevertheless, structural changes exist among these proteins and are revealed by circular dichroism in two different solvents (Fig. 4), and table I shows the results of the CD data analysis (31). In aqueous buffer (Fig. 4A), it can be deduced from the intensity of the negative 200 nm band that nonorganized structures are predominant (29). Table I reveals that there is no  helix in aqueous buffer excepted for Tat Mal and Tat Z2, which could have a short helix of eight to nine residues. In the presence of trifluoroethanol that mimic the membrane environment (30), three CD bands characteristic of  helix (29) appeared in all spectra (Fig. 4B). Table I shows that 19 to 30 residues are able to adopt an  helix structure as a function of the Tat variants. It is possible that this conformational heterogeneity helps Tat to cross the membrane barrier because most membrane proteins contain amphipathic  helix. It was shown that peptides derived from Tat can adopt such a conformation (32). Interestingly, the caboxymethylation of cysteines leads to an increase in  helix (Table I) and shows that the cysteines regions probably do not favor this secondary structure.

View larger version (57K): [in this window] [in a new window]   Fig. 3.   Electrophoretic mobility shift analysis for the synthetic Tat proteins. The protein concentration (ng/µl) is indicated at the top of each gel lane. Complexes and free RNA are identified as c and f, respectively. The same RNA preparation was used for the titration with the six proteins. A Tat Bru derivative with carboxymethylated cysteines (Bru Cm-Cys) was also tested. The equilibrium dissociation constants (Kd) were measured directly from these electrophoretic mobility shift assays. The Kd values vary from approximately 50 nM for both Tat Eli and Tat Mal to about 140 nM for Tat Oyi and Tat JR. In addition we noted that, beyond the variation of the Kd values, the binding profiles with the various proteins were somewhat different. For example, low concentrations of Tat Bru produced a well resolved single complex and only with rather high concentrations (>4.5 ng/µl) aggregates which were formed and which failed to enter the acrylamide gels. In contrast, multimeric complexes were easily identified with Tat Eli even when using low concentrations. Up to three retarded bands could be seen with Tat Eli and to a lower extent with Tat Jr. No such effects were observed with the shorter proteins such as Tat Bru and Tat Mal, for example, as well as with the longer protein Tat Oyi.

View larger version (22K): [in this window] [in a new window]   Fig. 4.   Circular dichroism. CD spectra of Tat Z2 (open triangle), Tat Oyi (solid triangle), Tat Bru (open circle), Tat Bru Cm-Cys (no mark), Tat Jr (solid circle), Tat Mal (open square), and Tat Eli (solid square) were measured from 260 to 178 nm with a 50 µM path length, either in phosphate buffer 20 mM (pH 4.5) (A) or in 50% TFE complemented with water (B). The differences observed in the CD spectra revealed a structural heterogeneity of Tat variants whatever the size. It is not possible to gather CD spectra in two categories constituted of short Tat (open mark) and long Tat (solid mark). In phosphate buffer, CD spectra are characterized by a negative band near 200 nm, typical of nonorganized structure. The intense magnitude of the 200 nm band observed with Tat Bru Cm-Cys show that cysteines play a structural role in Tat. In TFE buffer, CD spectra are characterized by three CD bands typical of  helix. It was reported that Tat Jr had its C-terminal extremity able to fit into a groove between the N-terminal and the basic regions (21). This particularity makes the Tat Jr C terminus more accessible to solvent and explains the intense magnitude of the  helix CD bands.

View this table: [in this window] [in a new window]   Table I Secondary structure analyses The percentage of secondary structures for each peptide was determined from the CD data analysis according to the method of Manavalan & Johnson (31). H, -helix; B, -sheet and/or extended structures; T, -turn; O, other structures.

The ability of our synthetic Tat to cross the membrane and trans-activate the HIV LTR was tested with transfected HeLa cells using two independent transfection assays. The gene reporter under the control of HIV-1 LTR was either -galactosidase (Fig. 5) or luciferase (data not shown). Tat Oyi was unable to trans-activate in both assays. All Tat proteins contain a cluster of seven cysteine residues (region 22-37), which are important for trans-activation because the mutation of one of them abolishes Tat trans-activation (18). Tat Oyi differs from all other variants by a substitution of Cys-22 to Ser-22. Tat Oyi has a sequence very close to Tat Jr, which does trans-activate in our test (Fig. 5). In support of the importance of the cysteines in the LTR trans-activation, Tat Bru Cm-Cys cannot trans-activate the HIV LTR (data not shown) but can bind TAR (Fig. 3).

View larger version (21K): [in this window] [in a new window]   Fig. 5.   Trans-activation assay with HeLa cells transfected with a LTR HIV-1 -gal. The LTR contains the up- and downstream DNA sequences required for the HIV transcription, and TAR is present at the beginning of the mRNA (33). The cellular cofactors required for HIV trans-activation are present in HeLa cells. Without Tat, there is a basal expression of -galactosidase that is indicated as a control (column C). The histograms show the trans-activation observed with the different Tat variants using two concentrations: 1 µM (light gray box) and 5 µM (gray box). In each case, Tat was added to the cell buffer, and therefore expression of -gal up to the control means that the synthetic Tat was able to cross the cytoplasmic and nucleus membranes, bind TAR, and interact with cellular cofactors. Only Tat Bru Cm-Cys (data not shown) and Tat Oyi failed in this experiment although they bind TAR (Fig. 1). Tat Mal and Tat Eli show a level of trans-activation three to four times higher to that of Tat Bru. Tat Z2, the closest of ancestral Tat proteins, has a low trans-activation level, and evolution could favor HIV-1 isolates with more efficient Tat. Similar results were obtained with another transfection assay using luciferase as gene reporter, and Tat Mal and Tat Eli at 1 µM did trans-activate the LTR to a level comparable with that obtained with a transfected pCMV-Tat (data not shown). The range of concentrations used in the different experiments were from 0.2 to 10 µM (data not shown). At 0.2 µM, only Tat Eli was showing a level of trans-activation significantly higher than the base level. At 10 µM, the six Tat were showing levels of trans-activation so high that it was impossible to see differences between them because there was saturation.

The major result of trans-activation tests was the high activity of Tat Mal and Tat Eli, which correlates with the high virulence of these two HIV-1 isolates. Interestingly, the long C-terminal extremity of Tat Eli seems to improve the trans-activation compared with Tat Mal (Fig. 5). However, the long C-terminal effect was not always observed with Tat Jr compared with Tat Bru as a function of the concentration (Fig. 5). In a different assay, the ability of Tat to be phosphorylated by PKR was verified (Fig. 6). Previous studies have shown only the phosphorylation to Tat Bru by PKR. Here we have further analyzed the six synthetic Tat variants with regard to their relation to PKR. When analyzed for their ability to serve as substrates for PKR, they proved to be different (Fig. 6). The Tat residues which are important for phosphorylation by PKR are Ser-62, Thr-64, and Ser-68 (17). The position of these three residues is well conserved in Tat corresponding to poorly virulent or nonvirulent HIV-1 isolates, such as Bru, Oyi, and Jr. In contrast to this, the virulent Tat variant Mal and Eli do not have these residues in similar positions. Fig. 6A shows that when PKR is activated with a synthetic RNA (poly(I)-poly(C), Tat Bru and Tat Oyi can be clearly phosphorylated but not Tat Mal and Tat Eli. Phosphorylation level is low for Tat Z2, which also differs from the STS consensus (Gly-62, Pro-68) but has kept the central Thr-64. Tat Jr also has a low phosphorylation level although it has the STS consensus. In a previous study, we mentioned that the C-terminal extremity of Tat Jr was unable to fit in a groove made by the N-terminal and the basic region as the C-terminal extremity of other long Tat variants (21). This structural particularity may disturb the interaction of Tat Jr with PKR. Fig. 6B shows that if PKR and Tat concentrations are increased, there is still no phosphorylation for Tat Mal. This experiment shows the high specificity of the PKR phosphorylation for Tat Bru compared with Tat Mal.

View larger version (69K): [in this window] [in a new window]   Fig. 6.   Activated PKR phosphorylates preferentially Tat variants from nonvirulent HIV isolates. A, monoclonal antibody-bound PKR on protein A-agarose (34) was first incubated for 15 min in the absence or presence of 1 µg/ml of poly(I)-poly(C) and further incubated for 15 min either as such (PKR only), in presence of eIF2, or 0.2 µg of the different Tat. After incubation, the 32P-labeled proteins were analyzed by SDS-polyacrylamide gel electrophoresis. The arrows indicate the position of eIF2 (35 kDa) and Tat (14 kDa), respectively. Whereas the ability of Tat BRU to be phosphorylated by PKR could be confirmed, only another Tat variant, TAT Oyi, was also clearly phosphorylated. A Tat Bru derivative with carboxymethylated cysteines (Bru Cm-Cys) was also tested. B, the phosphorylation reaction was performed as in panel A except that the concentrations of Tat and of bound PKR were increased (0.4 µg of Tat and Daudi cell extracts equivalent to 3 × 106 interferon-treated cells, respectively). An increase in the concentration of PKR or Tat could not lead to Tat Mal phosphorylation, whereas the phosphorylation of Tat Bru (with free cysteines) was clearly increased.

The trans-activation assays and the PKR-mediated phosphorylation assays demonstrate that our Tat variants behave as natural Tat proteins. Tat Bru can trans-activate HIV-1 LTR whereas Tat Oyi cannot, but they are both phosphorylated by PKR. Tat Mal and Tat Eli have a high trans-activation activity but are not phosphorylated by PKR. This demonstrates for the first time that the PKR-mediated phosphorylation of Tat is not related to the ability of Tat to trans-activate HIV-1 LTR. However, Tat Z2 and Tat Jr are poorly phosphorylated but donot have a high trans-activation activity. Only a low phosphorylation is perhaps enough to modify the Tat trans-activation activity, but it is possible that the correlation that we observed between the high trans-activation activity and virulent HIV strains could be also attributed to differences in uptake into the cell and/or phosphorylation by PKR. These studies show that few mutations can induce more efficient Tat proteins, which did correlate with the emergence of highly virulent HIV-1 strains in Africa. This result emphasizes the essential role played by Tat in the HIV infection and all the benefit that a Tat inhibitor could bring to AIDS therapies.

	ACKNOWLEDGEMENT

We are greatly indebted to Pierre Parouto for fruitful discussion.

	FOOTNOTES

^* This work was supported by l'Agence Nationale pour la Recherche sur le SIDA (ANRS), INSERM, the Pasteur Institute, and CNRS.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

^§ Recipient of a fellowship cofinanced from la Société Berroise de Raffinage (Shell Oil Company) and la région Provence Alpes Côtes-d'Azur.

Recipient of a fellowship from la Fondation pour la Recherche Médicale (FRM Sidaction).

^§§ To whom correspondence should be addressed. E-mail: loret{at}ibsm.cnrs-mrs.fr.

	ABBREVIATIONS

The abbreviations used are: HIV-1, human immunodeficiency virus type 1; Tat, HIV-1 trans-acting transcriptional activator; LTR, long terminal repeated noncoding sequences located at the two extremities of the HIV-1 provirus; TAR, RNA trans-activation response element; HPLC, high pressure liquid chromatography; TFA, trifluoroacetic acid; TFE, 2,2,2-trifluoroethanol; CD, circular dichroism; HMP, 4-hydroxymethyl-phenoxymethyl-copolystyrene-1% divinylbenzene; Fmoc, N-(9-fluorenyl)methoxycarbonyl.

	REFERENCES

TOP ABSTRACT INTRODUCTION MATERIALS AND METHODS RESULTS AND DISCUSSION REFERENCES

1. Fisher, A. G., Feinberg, M. B., Josephs, S. F., Harper, M. E., Marselle, L. M., Reyes, G., Gonda, M. M., Aldovini, A., Debouk, C., Gallo, R. C., and Wong-staal, F. (1986) Nature 320, 367-371[CrossRef][Medline] [Order article via Infotrieve]
2. Peterlin, B. M., Luciw, P. A., Barr, P. J., and Walker, M. D. (1986) Proc. Natl. Acad. Sci. U. S. A. 83, 9734-9738[Abstract/Free Full Text]
3. Berkhout, B., Gatignol, A., Rabson, A. B., and Jeang, K. T. (1990) Cell 62, 7257-7267
4. Loret, E. P., Georgel, P., Johnson, W. C., and Ho, P. S. (1992) Proc. Natl. Acad. Sci. U. S. A. 89, 9734-9738[Abstract/Free Full Text]
5. Vivès, E., Brodin, P., and Lebleu, B. (1997) J. Biol. Chem. 272, 16010-16017[Abstract/Free Full Text]
6. Efthymiadas, A., Briggs, L. J., and Jans, D. A. (1998) J. Biol. Chem. 273, 1623-1628[Abstract/Free Full Text]
7. Harrich, D., Ulich, C., Garcia-Martinez, L. F., and Gaynor, R. B. (1997) EMBO J. 6, 1224-1235[CrossRef]
8. Garcia-Martinez, L. F., Mavankal, G., Neveu, J. M., Lane, W. S., Ivanov, D., and Gaynor, R. B. (1997) EMBO J. 10, 2836-2850[CrossRef]
9. Yang, X., Gold, M. O., Tang, D. N., Lewis, D. E., Aguilar-Cordova, E., Rice, A. P., and Herrmann, C. H. (1997) Proc. Natl. Acad. Sci. U. S. A. 94, 12331-12336[Abstract/Free Full Text]
10. Westendorp, M. O., Frank, R., Ochsenbauer, C., Stricker, K., Dhein, J., Walczak, H., Debatin, K.-M., and Krammer, P. H. (1995) Nature 375, 497-500[CrossRef][Medline] [Order article via Infotrieve]
11. Ensoli, B., Gendelman, R., Markham, P., Fiorelli, V., Colombini, S., Raffeld, M., Cafaro, A., Chang, H. K., Brady, J. N., and Gallo, R. C. (1994) Nature 371, 674-680[CrossRef][Medline] [Order article via Infotrieve]
12. Howcroft, T. K., Strebel, K., Martin, M. A., and Singer, D. S. (1993) Science 260, 1320-1323[Abstract/Free Full Text]
13. Li, C. J., Friedman, D. J., Wang, C., Metelev, V., and Pardee, A. B. (1995) Science 268, 429-431[Abstract/Free Full Text]
14. Roy, S., Katze, M. G., Parkin, N. T., Edery, I., Hovanessian, A. G., and Sonenberg, N. (1990) Science 247, 1216-1219[Abstract/Free Full Text]
15. Benkirane, M., Neuveut, C., Chun, R. F., Smith, S. M., Samuel, C. E., Gatignol, A., and Jeang, K. T. (1997) EMBO 16, 611-624[CrossRef][Medline] [Order article via Infotrieve]
16. McMillan, N. A., Chun, R. F., Siderovski, D. P., Galabru, J., Toone, W. M., Samuel, C. E., Mak, T. W., Hovanessian, A. G., Jeang, K. T., and Williams, B. R. (1995) Virology 213, 413-424[CrossRef][Medline] [Order article via Infotrieve]
17. Brand, S., Kobayashi, R., and Mathews, M. B. (1997) J. Biol. Chem. 272, 8388-8395[Abstract/Free Full Text]
18. Jeang, K. T. (1996) HIV-1 Tat: Structure & Function, pp. 3-18, Los Alamos National Laboratory (Ed) Human Retroviruses & AIDS Compendium III
19. Barre-Sinoussi, F., Chermann, J. C., Rey, F., Nugeyre, M. T., Chamaret, S., Gruest, J., Dauguet, C., Axler-Blin, C., Vezinet-Brun, F., Rouzioux, C., Rozenbaum, W., and Montagnier, L. (1983) Science 220, 868-871[Abstract/Free Full Text]
20. Rosen, C. A., Sodroski, J. G., Goh, W. C, Dayton, A. I., Lippke, J., and Haseltine, W. A. (1986) Nature 319, 555-559[CrossRef][Medline] [Order article via Infotrieve]
21. Grégoire, C. J., and Loret, E. P. (1996) J. Biol. Chem. 271, 22641-22646[Abstract/Free Full Text]
22. Barany, G., and Merrifield, R. B. (1980) in The Peptide: Analysis, Synthesis, Biology (Gross, E., and Meinhofer, J., eds), Vol. 2, pp. 1-284, Academic Press, New York
23. O'Brien, W. A., Koyanagi, Y., Namazie, A., Zhao, J. Q., Diagne, A., Idler, K., Zack, J. A., and Chen, I. S. (1990) Nature 348, 69-73[CrossRef][Medline] [Order article via Infotrieve]
24. Huet, T., Dazza, M. C., Brun-Vezinet, F., Roelants, G. E., and Wain-Hobson, S. (1989) AIDS 3, 707-715[Medline] [Order article via Infotrieve]
25. Zhu, T., Korber, B. T., Nahmias, A. J., Hooper, E., Sharp, P. M., and Ho, D. D. (1998) Nature 391, 594-597[CrossRef][Medline] [Order article via Infotrieve]
26. Alizon, M., Wain-Hobson, S., Montagnier, L., and Sonigo, P. (1986) Cell 46, 63-74[CrossRef][Medline] [Order article via Infotrieve]
27. Chun, R., Glabe, C. G., and Fan, H. (1990) J. Virol. 64, 3074-3077[Abstract/Free Full Text]
28. Jeyapaul, J., Reddy, M. R., and Khan, S. A. (1990) Proc. Natl. Acad. Sci. U. S. A. 87, 7030-7034[Abstract/Free Full Text]
29. Johnson, W. C., Jr. (1985) Methods Biochem. Anal. 31, 61-163[Medline] [Order article via Infotrieve]
30. Urry, D. W. (1972) Biochim. Biophys. Acta 265, 115-168[Medline] [Order article via Infotrieve]
31. Manavalan, P., and Johnson, W. C., Jr. (1987) Anal. Biochem. 167, 76-85[CrossRef][Medline] [Order article via Infotrieve]
32. Loret, E. P., Vives, E., Ho, P. S., Rochat, H., van Rietschoten, J., and Johnson, W. C., Jr. (1991) Biochemistry 30, 6013-6023[CrossRef][Medline] [Order article via Infotrieve]
33. Clavel, F., and Charneau, P. (1994) J. Virol 68, 1179-1185[Abstract/Free Full Text]
34. Laurent, A. G., Krust, B., Galabru, J., Svab, J., and Hovanessian, A. G. (1985) Proc. Natl. Acad. Sci. U. S. A. 82, 4341-4345[Abstract/Free Full Text]